- Home
- LGVN vs LSTA Comparison
LGVN vs LSTA Comparison
Compare LGVN & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- LSTA
- Stock Information
- Founded
- LGVN 2014
- LSTA 1980
- Country
- LGVN United States
- LSTA United States
- Employees
- LGVN N/A
- LSTA N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- LSTA Misc Health and Biotechnology Services
- Sector
- LGVN Health Care
- LSTA Health Care
- Exchange
- LGVN Nasdaq
- LSTA Nasdaq
- Market Cap
- LGVN 23.4M
- LSTA 20.9M
- IPO Year
- LGVN 2021
- LSTA N/A
- Fundamental
- Price
- LGVN $1.30
- LSTA $2.94
- Analyst Decision
- LGVN Strong Buy
- LSTA Strong Buy
- Analyst Count
- LGVN 3
- LSTA 1
- Target Price
- LGVN $8.67
- LSTA $15.00
- AVG Volume (30 Days)
- LGVN 138.8K
- LSTA 9.3K
- Earning Date
- LGVN 08-13-2025
- LSTA 08-11-2025
- Dividend Yield
- LGVN N/A
- LSTA N/A
- EPS Growth
- LGVN N/A
- LSTA N/A
- EPS
- LGVN N/A
- LSTA N/A
- Revenue
- LGVN $2,225,000.00
- LSTA $1,000,000.00
- Revenue This Year
- LGVN N/A
- LSTA N/A
- Revenue Next Year
- LGVN $51.48
- LSTA N/A
- P/E Ratio
- LGVN N/A
- LSTA N/A
- Revenue Growth
- LGVN 127.50
- LSTA N/A
- 52 Week Low
- LGVN $1.14
- LSTA $1.87
- 52 Week High
- LGVN $6.40
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- LGVN 50.13
- LSTA 66.20
- Support Level
- LGVN $1.15
- LSTA $2.36
- Resistance Level
- LGVN $1.32
- LSTA $2.69
- Average True Range (ATR)
- LGVN 0.09
- LSTA 0.20
- MACD
- LGVN 0.01
- LSTA 0.01
- Stochastic Oscillator
- LGVN 45.31
- LSTA 90.77
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.